Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684823 · ClinicalTrials.gov registry record · NA
The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis
A NA study of Cystic Fibrosis and Adherence, Medication, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04684823: Completed NA study of Cystic Fibrosis and Adherence, Medication, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04684823 is a NA study of Cystic Fibrosis and Adherence, Medication that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 12 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04684823, a NA study of Cystic Fibrosis and Adherence, Medication, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.
Primary Outcome
Tracking of medication compliance over the time where the Patch Cap and Patch App are used by determining number of days compliance
Conditions Studied
Interventions
- DEVICE Patch Cap
- DEVICE Patch App
Study Locations (1)
Texas
- The University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2021-12-27 |
| Phase | NA |
What the finished NCT04684823 record still lists
NCT04684823 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Patch Cap is the first listed.
NCT04684823 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04684823 about?
NCT04684823 is a clinical study titled "The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis". This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.
What is the current status of trial NCT04684823?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2021-01-15. Estimated completion is 2021-12-27.
What conditions does trial NCT04684823 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Adherence, Medication.
What interventions are being tested in trial NCT04684823?
The interventions under investigation include: Patch Cap (DEVICE), Patch App (DEVICE).
Who is sponsoring clinical trial NCT04684823?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04684823 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04684823's enrollment target sits among peer trials
12 152nd of 169 higher than 15 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
FEED-Cystic Fibrosis (FEED-CF)
RECRUITING · NA
-
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
RECRUITING · NA
-
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
RECRUITING · NA
-
Lung Transplant READY CF 2: CARING CF Ancillary RCT
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI